Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel
An. bras. dermatol
;
95(2): 221-237, Mar.-Apr. 2020. tab, graf
Artigo
em Inglês
| LILACS, ColecionaSUS
| ID: biblio-1130848
ABSTRACT
Abstract With the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Dermatopatias
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Estudo de etiologia
/
Guia de Prática Clínica
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
An. bras. dermatol
Ano de publicação:
2020
Tipo de documento:
Artigo
Instituição/País de afiliação:
Centro Paulista de Oncologia/BR
/
Hospital Beneficência Portuguesa de São Paulo/BR
/
Hospital Sírio-Libanês/BR
/
Santa Casa de Misericórdia de São Paulo/BR
/
Universidade de São Paulo/BR
Similares
MEDLINE
...
LILACS
LIS